Are Prostate Cancer patients Stressed, Anxious or Depressed? Time to find out
Tuesday, 11th October 2016
Gary has organised two phlebotomists who regularly work at our PSA testing sessions to help at a session to be held in Stockport this coming Saturday 15th October. This session will enable scientists to establish psychological and physiological factors that could impact on the efficacy of the future prostate cancer vaccine that could be ready for clinical human trials as early as the end of 2017.
Stephanie McArdle says "The purpose of the event on Saturday is to determine whether the participants are stressed and to establish a reliable method of measuring their stress level." The event will also allow Dr McArdle to determine whether prostate cancer patients have high level of inflammation-related molecules in their blood (which would be indicative of chronic inflammation) both of which might influence their immune system.
This could be of importance because the team at Nottingham Trent University's John van Geest Cancer Research Centre believes that stress and/or chronic inflammation in a patient before vaccination may significantly impact on the efficacy of a future Prostate Cancer vaccine. In fact, Stephanie believes that the success of any vaccine will strongly depend on taking into account the well-being of the patient BEFORE vaccination and therefore if patients are found to be stressed it will be necessary to implement some form of stress management before vaccination takes place.
A total of 30 Prostate Cancer (20 from the Stockport area plus 10 recruited by the Nottingham team) have been enrolled in the study. Another 10 participants with no known disease will be used as controls. On Saturday, the volunteers will complete a series of psychometric questionnaires and have an EEG recording to assess the stress level of each person. Participants will also be asked to perform 6 saliva swabs over the course of 2 days in order to assess cortisol level, a hormone linked with stress. A blood sample will also be taken (by our phlebotomists) on that day in order to assess the level of inflammation-related molecules present in the plasma.
Our group is pleased to be involved with Stephanie's research since this study is the first of its kind where the patients’ well-being is being considered as a potentially important factor that might need addressing in order to maximise the success of any future vaccine trial. We wish her and her team every success in their research.
No upcoming events.